Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17826364rdf:typepubmed:Citationlld:pubmed
pubmed-article:17826364lifeskim:mentionsumls-concept:C0031336lld:lifeskim
pubmed-article:17826364lifeskim:mentionsumls-concept:C0013058lld:lifeskim
pubmed-article:17826364lifeskim:mentionsumls-concept:C0205307lld:lifeskim
pubmed-article:17826364lifeskim:mentionsumls-concept:C0205177lld:lifeskim
pubmed-article:17826364lifeskim:mentionsumls-concept:C1527148lld:lifeskim
pubmed-article:17826364lifeskim:mentionsumls-concept:C1555029lld:lifeskim
pubmed-article:17826364lifeskim:mentionsumls-concept:C0205390lld:lifeskim
pubmed-article:17826364lifeskim:mentionsumls-concept:C1522240lld:lifeskim
pubmed-article:17826364lifeskim:mentionsumls-concept:C0185125lld:lifeskim
pubmed-article:17826364lifeskim:mentionsumls-concept:C0936012lld:lifeskim
pubmed-article:17826364lifeskim:mentionsumls-concept:C1550600lld:lifeskim
pubmed-article:17826364lifeskim:mentionsumls-concept:C1553890lld:lifeskim
pubmed-article:17826364lifeskim:mentionsumls-concept:C0796512lld:lifeskim
pubmed-article:17826364lifeskim:mentionsumls-concept:C2350862lld:lifeskim
pubmed-article:17826364pubmed:issue1-2lld:pubmed
pubmed-article:17826364pubmed:dateCreated2007-10-9lld:pubmed
pubmed-article:17826364pubmed:abstractTextABT-578, an active pharmaceutical ingredient (API), is a semi-synthetic tetrazole derivative of the fermented polyene macrolide rapamycin. Reverse phase (RP)-HPLC-UV-MS and normal phase (NP)-HPLC-UV-MS methods employing an LC/MSD trap with electrospray ionization (ESI) have been developed to track and map all significant impurities from the synthetic process. Trace-level tracking of key impurities occurring at various process points was achieved using complimentary methodologies, including a stability indicating reverse phase HPLC method capable of separating at least 25 starting materials and process-related impurities from the API (YMC-Pack Phenyl column, UV-MS, 210 nm) and a targeted reverse phase HPLC method capable of separating very polar compounds from crude reaction mixtures (Phenomenex Synergi Polar RP column, UV, 265 nm). In addition, a normal phase HPLC method condition with post-column modifier infusion is described for the separation of epimeric impurities, and analysis of aqueous-sensitive reactive species (YMC-Pack SIL column, UV-MS, 278 nm). Process control strategies were established with these combinations of analytical technologies for impurities analyses to enable a rich understanding of the ABT-578 process.lld:pubmed
pubmed-article:17826364pubmed:languageenglld:pubmed
pubmed-article:17826364pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17826364pubmed:citationSubsetIMlld:pubmed
pubmed-article:17826364pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17826364pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17826364pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17826364pubmed:statusMEDLINElld:pubmed
pubmed-article:17826364pubmed:monthOctlld:pubmed
pubmed-article:17826364pubmed:issn1570-0232lld:pubmed
pubmed-article:17826364pubmed:authorpubmed-author:ZhouCasey...lld:pubmed
pubmed-article:17826364pubmed:authorpubmed-author:ChenYongYlld:pubmed
pubmed-article:17826364pubmed:authorpubmed-author:LeannaM...lld:pubmed
pubmed-article:17826364pubmed:authorpubmed-author:RasmussenMich...lld:pubmed
pubmed-article:17826364pubmed:authorpubmed-author:DhaonMadhup...lld:pubmed
pubmed-article:17826364pubmed:authorpubmed-author:BrillGregory...lld:pubmed
pubmed-article:17826364pubmed:authorpubmed-author:BenzNancy JNJlld:pubmed
pubmed-article:17826364pubmed:authorpubmed-author:BruzekJames...lld:pubmed
pubmed-article:17826364pubmed:authorpubmed-author:BellettiniJoh...lld:pubmed
pubmed-article:17826364pubmed:issnTypePrintlld:pubmed
pubmed-article:17826364pubmed:day15lld:pubmed
pubmed-article:17826364pubmed:volume858lld:pubmed
pubmed-article:17826364pubmed:ownerNLMlld:pubmed
pubmed-article:17826364pubmed:authorsCompleteYlld:pubmed
pubmed-article:17826364pubmed:pagination106-17lld:pubmed
pubmed-article:17826364pubmed:dateRevised2008-6-5lld:pubmed
pubmed-article:17826364pubmed:meshHeadingpubmed-meshheading:17826364...lld:pubmed
pubmed-article:17826364pubmed:meshHeadingpubmed-meshheading:17826364...lld:pubmed
pubmed-article:17826364pubmed:meshHeadingpubmed-meshheading:17826364...lld:pubmed
pubmed-article:17826364pubmed:meshHeadingpubmed-meshheading:17826364...lld:pubmed
pubmed-article:17826364pubmed:meshHeadingpubmed-meshheading:17826364...lld:pubmed
pubmed-article:17826364pubmed:meshHeadingpubmed-meshheading:17826364...lld:pubmed
pubmed-article:17826364pubmed:meshHeadingpubmed-meshheading:17826364...lld:pubmed
pubmed-article:17826364pubmed:meshHeadingpubmed-meshheading:17826364...lld:pubmed
pubmed-article:17826364pubmed:meshHeadingpubmed-meshheading:17826364...lld:pubmed
pubmed-article:17826364pubmed:year2007lld:pubmed
pubmed-article:17826364pubmed:articleTitleNormal phase and reverse phase HPLC-UV-MS analysis of process impurities for rapamycin analog ABT-578: application to active pharmaceutical ingredient process development.lld:pubmed
pubmed-article:17826364pubmed:affiliationD-R45T, Process Analytical Chemistry, Global Pharmaceutical Research and Development, Abbott Laboratories, North Chicago, IL 60064-4000, USA. yong.chen@abbott.comlld:pubmed
pubmed-article:17826364pubmed:publicationTypeJournal Articlelld:pubmed